Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced that CEO Lisa Conte will present virtually at the Life Sciences Virtual Investor Forum on Thursday, March 12, 2026 at 2:00 PM Eastern. Registration is available through the conference site and a replay of the webcast will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction – JAGX
On the day this news was published, JAGX gained 19.99%, reflecting a significant positive market reaction. Argus tracked a peak move of +23.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $421K to the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: AZTR down, while XRTX and GRI are up, and scanner names like CNSP and OGEN also move in both directions. With JAGX down 4.11%, this pattern points to stock-specific dynamics rather than a unified biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Debt restructuring | Positive | -16.9% | Restructured royalties and debt, extended maturities, and extinguished 48,212 warrants. |
| Mar 03 | Licensing payment | Positive | -23.2% | Received additional <b>$3.0M</b> from Future Pak under Mytesi and Canalevia-CA1 agreement. |
| Mar 02 | Dividend record date | Neutral | -0.8% | Reminder of record date for Special Stock Dividend of Series O preferred shares. |
| Feb 18 | Special dividend | Positive | +0.6% | Announced Special Stock Dividend of Series O preferred and noted crofelemer clinical progress. |
| Jan 22 | Strategy update | Positive | -9.8% | Outlined sharp focus on rare intestinal failure diseases supported by <b>$16M</b> license funds. |
Recent history shows frequent negative price reactions following balance sheet improvements, licensing deals, and strategic updates, suggesting the stock has often sold off on ostensibly constructive news.
Over the past few months, Jaguar Health highlighted non-dilutive funding and strategic refocusing. An initial $16M license payment and later a $3.0M payment from Future Pak supported a pivot toward crofelemer for rare intestinal failure. The company restructured royalties and debt, extinguishing 48,212 warrants and pushing out maturities. Special Series O preferred stock dividends were declared to address dilution concerns. Against this backdrop, the latest investor forum presentation mainly serves to communicate near-term catalysts to the market.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-10-03 allows Jaguar Health to register and potentially issue securities more flexibly. The filing references prior private placements, pre-funded warrants, and common 19.99% beneficial ownership limits, highlighting ongoing use of structured financing tools and preferred stock designations.
Market Pulse Summary
The stock surged +20.0% in the session following this news. A strong positive reaction aligns with the company’s need to re-engage investors after multiple balance sheet restructurings, license deals, and Nasdaq compliance challenges. Prior news often saw selling despite constructive developments, so sustained gains would depend on how convincingly management outlines near-term catalysts, financing flexibility under the S-3, and progress for crofelemer in rare intestinal failure indications.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com.
Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum
When: Thursday, March 12, 2026 at 2:00 PM Eastern
Registration link for conference: Click Here
Replay: A replay of the webcast will be available following the conclusion of the conference.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the March 2026 conference listed above. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Jaguar Health (JAGX) present at the Life Sciences Virtual Investor Forum?
How can investors register for Jaguar Health's (JAGX) virtual presentation on March 12, 2026?
Will Jaguar Health (JAGX) provide a replay of the March 12, 2026 presentation?
Who from Jaguar Health (JAGX) will present at the Life Sciences Virtual Investor Forum?
